Pure Bioscience, Inc. (PURE) stock
PUREOTCMiscellaneous Chemical ProductsFiscal year ends July 31
$0.07−0.01 (-12.10%)
Close on Oct 19, 2026Market cap $8.67MP/E –Yield –
Pure Bioscience operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Pure Bioscience's operating cash flow for the twelve months ending Jul 31, 2026 was -$1.74M. For fiscal 2026 it was -$1.74M. The highest annual figure on record is $669.00K in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jul 31, 2026 | -$1.74M | – |
| FY2025 | Jul 31, 2025 | -$2.02M | – |
| FY2024 | Jul 31, 2024 | -$2.53M | – |
| FY2023 | Jul 31, 2023 | -$3.28M | – |
| FY2022 | Jul 31, 2022 | -$2.42M | – |
| FY2021 | Jul 31, 2021 | -$1.17M | -274.4% |
| FY2020 | Jul 31, 2020 | $669.00K | – |
| FY2019 | Jul 31, 2019 | -$2.99M | – |
| FY2018 | Jul 31, 2018 | -$3.89M | – |
| FY2017 | Jul 31, 2017 | -$4.56M | – |
| FY2016 | Jul 31, 2016 | -$4.99M | – |
| FY2015 | Jul 31, 2015 | -$6.06M | – |
| FY2014 | Jul 31, 2014 | -$6.33M | – |
| FY2013 | Jul 31, 2013 | -$3.90M | – |
| FY2012 | Jul 31, 2012 | -$5.59M | – |
| FY2011 | Jul 31, 2011 | -$6.12M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jul 31, 2026 | -$414.00K | – |
| Q3 FY2026CQ1 2026 | Apr 30, 2026 | -$468.00K | – |
| Q2 FY2026CQ4 2025 | Jan 31, 2026 | -$606.00K | – |
| Q1 FY2026CQ3 2025 | Oct 31, 2025 | -$250.00K | – |
| Q4 FY2025CQ2 2025 | Jul 31, 2025 | -$456.00K | – |
| Q3 FY2025CQ1 2025 | Apr 30, 2025 | -$512.00K | – |
| Q2 FY2025CQ4 2024 | Jan 31, 2025 | -$544.00K | – |
| Q1 FY2025CQ3 2024 | Oct 31, 2024 | -$503.00K | – |
| Q4 FY2024CQ2 2024 | Jul 31, 2024 | -$593.00K | – |
| Q3 FY2024CQ1 2024 | Apr 30, 2024 | -$615.00K | – |
| Q2 FY2024CQ4 2023 | Jan 31, 2024 | -$883.00K | – |
| Q1 FY2024CQ3 2023 | Oct 31, 2023 | -$440.00K | – |
| Q4 FY2023CQ2 2023 | Jul 31, 2023 | -$744.00K | – |
| Q3 FY2023CQ1 2023 | Apr 30, 2023 | -$665.00K | – |
| Q2 FY2023CQ4 2022 | Jan 31, 2023 | -$967.00K | – |
| Q1 FY2023CQ3 2022 | Oct 31, 2022 | -$902.00K | – |
| Q4 FY2022CQ2 2022 | Jul 31, 2022 | -$603.00K | – |
| Q3 FY2022CQ1 2022 | Apr 30, 2022 | -$609.00K | – |
| Q2 FY2022CQ4 2021 | Jan 31, 2022 | -$630.00K | – |
| Q1 FY2022CQ3 2021 | Oct 31, 2021 | -$576.00K | – |
| Q4 FY2021CQ2 2021 | Jul 31, 2021 | -$412.00K | -122.5% |
| Q3 FY2021CQ1 2021 | Apr 30, 2021 | -$347.00K | – |
| Q2 FY2021CQ4 2020 | Jan 31, 2021 | -$209.00K | – |
| Q1 FY2021CQ3 2020 | Oct 31, 2020 | -$199.00K | – |
| Q4 FY2020CQ2 2020 | Jul 31, 2020 | $1.83M | – |
| Q3 FY2020CQ1 2020 | Apr 30, 2020 | -$224.00K | – |
| Q2 FY2020CQ4 2019 | Jan 31, 2020 | -$614.00K | – |
| Q1 FY2020CQ3 2019 | Oct 31, 2019 | -$324.00K | – |
| Q4 FY2019CQ2 2019 | Jul 31, 2019 | -$656.00K | – |
| Q3 FY2019CQ1 2019 | Apr 30, 2019 | -$833.00K | – |
| Q2 FY2019CQ4 2018 | Jan 31, 2019 | -$441.00K | – |
| Q1 FY2019CQ3 2018 | Oct 31, 2018 | -$1.06M | – |
| Q4 FY2018CQ2 2018 | Jul 31, 2018 | -$664.00K | – |
| Q3 FY2018CQ1 2018 | Apr 30, 2018 | -$1.10M | – |
| Q2 FY2018CQ4 2017 | Jan 31, 2018 | -$1.09M | – |
| Q1 FY2018CQ3 2017 | Oct 31, 2017 | -$1.03M | – |
| Q4 FY2017CQ2 2017 | Jul 31, 2017 | -$1.17M | – |
| Q3 FY2017CQ1 2017 | Apr 30, 2017 | -$1.17M | – |
| Q2 FY2017CQ4 2016 | Jan 31, 2017 | -$1.18M | – |
| Q1 FY2017CQ3 2016 | Oct 31, 2016 | -$1.05M | – |
See a number that looks wrong?